Literature DB >> 8449952

Identification of a major binding site for complement C3 on the IgG1 heavy chain.

J M Shohet1, P Pemberton, M C Carroll.   

Abstract

Activation of the alternative pathway of complement by immune complexes involves the covalent attachment of the third component (C3) to the IgG heavy chain. In order to localize the site/sites of attachment, adducts of human C3.IgG were digested in situ with endoproteinase Lys-C and Staphylococcus aureus V8 protease, and the fragments were analyzed. The dimeric peptide containing the covalent bond, identified by alkylation of the free thiol group (Cys1010) with iodo[14C]acetamide, was isolated by high-performance liquid chromatography fractionation. A double sequence with NH2 termini corresponding to position 134 of IgG heavy chain and position 1002 of the C3 alpha' chain was found by analysis with automated Edman degradation. The intact dimeric peptide had a mass of 3453 Da and was composed of IgG and C3 fragments with predicted sizes of 23 and 12 residues, respectively. The IgG peptide includes a cluster of six potential acceptor sites for ester bond formation. Thus, it appears that C3 binding is limited to a single region within the CH1 domain of the IgG1 heavy chain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8449952

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD).

Authors:  Robert J Boackle; Quang L Nguyen; Renata S Leite; Xiaofeng Yang; Jana Vesely
Journal:  Mol Immunol       Date:  2005-03-05       Impact factor: 4.407

Review 2.  Regulation of antibody effector functions through IgG Fc N-glycosylation.

Authors:  Isaak Quast; Benjamin Peschke; Jan D Lünemann
Journal:  Cell Mol Life Sci       Date:  2016-09-17       Impact factor: 9.261

Review 3.  Heavy chain deposition disease: an overview.

Authors:  Yuji Oe; Jun Soma; Hiroshi Sato; Sadayoshi Ito
Journal:  Clin Exp Nephrol       Date:  2013-05-08       Impact factor: 2.801

4.  Decreased infectivity despite unaltered C3 binding by a DeltahbhA mutant of Mycobacterium tuberculosis.

Authors:  Stacey L Mueller-Ortiz; Eliud Sepulveda; Margaret R Olsen; Chinnaswamy Jagannath; Audrey R Wanger; Steven J Norris
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.

Authors:  J Wada; N Shintani; K Kikutani; T Nakae; T Yamauchi; K Takechi
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

6.  High-affinity binding sites for related fibroblast growth factor ligands reside within different receptor immunoglobulin-like domains.

Authors:  H G Cheon; W J LaRochelle; D P Bottaro; W H Burgess; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

Review 7.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

8.  The role of the carbohydrate chains in complement (C3) fixation by solid-phase-bound human IgA.

Authors:  E B Nikolova; M Tomana; M W Russell
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

9.  Purification and characterization of a human membrane protein that activates the alternative complement pathway and allows the deposition of homologous complement C3.

Authors:  M Matsumoto; F Yamashita; K Iida; M Tomita; T Seya
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

10.  Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.

Authors:  Mariana Lopes dos Santos; Fernanda Perez Yeda; Lilian Rumi Tsuruta; Bruno Brasil Horta; Alécio A Pimenta; Theri Leica Degaki; Ibere C Soares; Maria Carolina Tuma; Oswaldo Keith Okamoto; Venancio A F Alves; Lloyd J Old; Gerd Ritter; Ana Maria Moro
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.